HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TECX
Tectonic Therapeutic, Inc.
There isn't enough reported data to score TECX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TECX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
TECX's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TECX PE Valuation
TECX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TECX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect TECX's earnings, revenue and profitability to hold roughly steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TECX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.63 | -$0.47 |
| Q2 2026 | -$4.57 | -$0.23 |
| Q1 2026 | -$4.46 | +$3.15 |
| Q4 2025 | -$4.05 | +$4.43 |
| Q3 2025 | -$4.16 | +$5.58 |
| Q2 2025 | -$4.34 | +$9.96 |
| Q1 2025 | -$7.61 | -192% |
| Q4 2024 | -$8.48 | -362% |
TECX is still losing money, but far less than before: $4.63 per share over the past year, against $39.72 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TECX Quarterly Revenue
TECX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TECX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TECX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.9M | +$3.1M |
| Q2 2026 | -$21.5M | -$6.8M |
| Q1 2026 | -$18.4M | -$5.3M |
| Q4 2025 | -$14.5M | +$2.4M |
| Q3 2025 | -$18M | +$1.8M |
| Q2 2025 | -$14.7M | +$367K |
| Q1 2025 | -$13.1M | -$5.5M |
| Q4 2024 | -$16.8M | -$8.8M |
TECX has burned cash in almost every quarter: −$69M over the past year, against −$63M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TECX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TECX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +740K shares |
| 1 year | +5.3% | +991K shares |
| 3 years | +434% | +16M shares |
| 5 years | +555% | +16.7M shares |
TECX has 20M diluted shares, up 5.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TECX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -3.3x | Net Cash |
| Q4 2023 | -9.1x | Net Cash |
TECX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TECX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 7.9 | Oversold |
TECX's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TECX PE vs Healthcare Sector
| Metric | TECX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TECX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TECX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.5 | 2% below |
| 20 week MA | $28.1 | 25% below |
| 50 week MA | $27.0 | 22% below |
| 100 week MA | $25.8 | 19% below |
| 200 week MA | $22.3 | 5.7% below |
TECX is in a downtrend: it's below all five of its weekly moving averages, and 5.7% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TECX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $235.0 | $176.2 | -25% |
| 2021 | $176.2 | $46.9 | -73% |
| 2022 | $46.9 | $9.12 | -81% |
| 2023 | $9.12 | $16.3 | +79% |
| 2024 | $16.3 | $47.0 | +188% |
| 2025 | $47.0 | $20.9 | -56% |
| 2026 YTD | $20.9 | $21.0 | +0.8% |
TECX has the edge over HIMS on returns for 2026, with the stronger performance.